Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

Breast Cancer Research and Treatment

Volumn 117, Issue 3, 2009, Pages 571-575

  Lynn Henry, N ^a,b   Rae, James M ^b   Li, Lang ^c   Azzouz, Faouzi ^c   Skaar, Todd C ^c   Desta, Zereunesay ^c   Sikora, Matthew J ^b   Philips, Santosh ^c   Nguyen, Anne T ^c   Storniolo, Anna Maria ^d   Hayes, Daniel F ^a,b   Flockhart, David A ^c   Stearns, Vered ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; CYP2D6; Genotype; Hot flash; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; TAMOXIFEN;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

BREAST NEOPLASMS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOT FLASHES; HUMANS; POLYMORPHISM, GENETIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 70349575970     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0309-1     Document Type: Article

References (21)

1. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618 10.1056/NEJM199811263392207 9828250 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D (Pubitemid 28536137)
2. Y Jin Z Desta V Stearns, et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 15632378 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D
3. V Stearns MD Johnson JM Rae, et al. 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 14652237 1:CAS:528:DC%2BD3sXpvVelsbc%3D
4. MP Goetz JM Rae VJ Suman, et al. 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 10.1200/JCO.2005.03.3266 16361630 10.1200/JCO.2005.03.3266 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D (Pubitemid 46260189)
5. W Schroth L Antoniadou P Fritz, et al. 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187 5193 10.1200/JCO.2007.12.2705 18024866 10.1200/JCO.2007.12.2705 1:CAS:528:DC%2BD2sXhsVKnsbzN (Pubitemid 350232249)
6. HS Lim H Ju Lee K Seok Lee, et al. 2007 Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer J Clin Oncol 25 3837 3845 10.1200/JCO.2007.11.4850 17761971 10.1200/JCO.2007.11. 4850 1:CAS:528:DC%2BD2sXhtFanu7zK (Pubitemid 47477258)
7. S Nowell J Ahn JM Rae, et al. 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 249 258 10.1007/s10549-004-7751-x 15952058 10.1007/s10549-004-7751-x 1:CAS:528:DC%2BD2MXltFGqsLs%3D (Pubitemid 40903087)
8. P Wegman L Vainikka O Stal, et al. 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 R284 R290 10.1186/bcr993 15987423 10.1186/bcr993 1:CAS:528: DC%2BD2MXitF2qtr0%3D
9. P Wegman S Elingarami J Carstensen, et al. 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 R7 10.1186/bcr1640 17244352 10.1186/bcr1640 (Pubitemid 350215154)
10. MP Goetz V Suman M Ames, et al. 2009 Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial Cancer Res 69 suppl 6037 abstract
11. JE Mortimer SW Flatt BA Parker, et al. 2008 Tamoxifen, hot flashes and recurrence in breast cancer Breast Cancer Res Treat 108 421 426 10.1007/s10549-007-9612-x 17541741 10.1007/s10549-007-9612-x 1:CAS:528:DC%2BD1cXjsFGisbw%3D
12. J Cuzick I Sestak D Cella, et al. 2008 Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial Lancet Oncol 9 1143 1148 10.1016/S1470-2045(08)70259-6 18976959 10.1016/S1470-2045(08)70259-6 1:CAS:528:DC%2BD1cXhsVWrsL7J
13. Y Jin DF Hayes L Li, et al. 2008 Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy J Clin Oncol 26 5849 5854 10.1200/JCO.2008.16.8377 19018086 10.1200/JCO.2008.16. 8377
14. S Borges Z Desta L Li, et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 10.1016/j.clpt.2006.03.013 16815318 10.1016/j.clpt.2006.03.013 1:CAS:528:DC%2BD28Xms1enu7k%3D (Pubitemid 43946844)
15. G Finck DL Barton CL Loprinzi, et al. 1998 Definitions of hot flashes in breast cancer survivors J Pain Symptom Manage 16 327 333 10.1016/S0885-3924(98) 00090-6 9846028 10.1016/S0885-3924(98)00090-6 1:STN:280:DyaK1M%2Fmt1Cmug%3D%3D (Pubitemid 28545914)
16. JA Sloan CL Loprinzi PJ Novotny, et al. 2001 Methodologic lessons learned from hot flash studies J Clin Oncol 19 4280 4290 11731510 1:STN:280: DC%2BD3MnosFWgtA%3D%3D
17. MJ Blake A Gaedigk RE Pearce, et al. 2007 Ontogeny of dextromethorphan O- and N-demethylation in the first year of life Clin Pharmacol Ther 81 510 516 10.1038/sj.clpt.6100101 17301735 10.1038/sj.clpt.6100101 1:CAS:528: DC%2BD2sXkvFymu7w%3D (Pubitemid 46452306)
18. A Gaedigk SD Simon RE Pearce, et al. 2008 The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 234 242 10.1038/sj.clpt.6100406 17971818 10.1038/sj.clpt. 6100406 1:STN:280:DC%2BD1c%2FkslCqug%3D%3D
19. L Madlensky SW Flatt L Natarajan, et al. 2009 Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen Cancer Res 69 suppl 6045 abstract
20. NT Snider MJ Sikora C Sridar, et al. 2008 The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6 J Pharmacol Exp Ther 327 538 545 10.1124/jpet.108.141796 18698000 10.1124/jpet.108.141796 1:CAS:528:DC%2BD1cXhtlWns7vN
21. CL Loprinzi KM Zahasky JA Sloan, et al. 2000 Tamoxifen-induced hot flashes Clin Breast Cancer 1 52 56 10.3816/CBC.2000.n.004 11899390 10.3816/CBC.2000.n.004 1:STN:280:DC%2BD387mvVarsg%3D%3D